
Benjamin Bonnard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3231943/publications.pdf Version: 2024-02-01



RENIAMIN RONNARD

#	Article	IF	CITATIONS
1	Mineralocorticoid Receptor and Cardiovascular Disease. American Journal of Hypertension, 2018, 31, 1165-1174.	2.0	80
2	Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. Journal of Molecular and Cellular Cardiology, 2018, 121, 124-133.	1.9	32
3	Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annual Review of Physiology, 2022, 84, 585-610.	13.1	31
4	Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. Experimental Eye Research, 2019, 187, 107747.	2.6	25
5	The Absence of Endothelial Sodium Channel α (αENaC) Reduces Renal Ischemia/Reperfusion Injury. International Journal of Molecular Sciences, 2019, 20, 3132.	4.1	17
6	A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. Circulation Research, 2020, 127, e80-e93.	4.5	17
7	Neutrophil Gelatinase-Associated Lipocalin From Macrophages Plays a Critical Role in Renal Fibrosis Via the CCL5 (Chemokine Ligand 5)-Th2 Cells-IL4 (Interleukin 4) Pathway. Hypertension, 2022, 79, 352-364.	2.7	13
8	Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models. Scientific Reports, 2021, 11, 2591.	3.3	11
9	Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve. International Journal of Molecular Sciences, 2020, 21, 5372.	4.1	10
10	Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice. Frontiers in Physiology, 2022, 13, 859812.	2.8	9
11	Endothelial sodium channel activation mediates DOCA-salt-induced endothelial cell and arterial stiffening. Metabolism: Clinical and Experimental, 2022, 130, 155165.	3.4	7
12	Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. International Journal of Molecular Sciences, 2022, 23, 6680.	4.1	2